The present study demonstrates that IRF4 and cMyc expression is driven by Sp1 overexpressed in MM cells, and that Sp1 degradation by combinatory treatment with panobinostat and proteasome inhibitors causes substantial reduction of IRF4 and cMyc, which at least in part contributes to the induction of MM cell death. Here, SP1 is linked to Miyoshi myopathy.